South Australian Neonatal Medication Guidelines

Probiotic (Infloran®)

bifidobacterium bifidum and lactobacillus acidophilus capsule

© Department for Health and Wellbeing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

• The use of interpreter services where necessary,
• Advising consumers of their choice and ensuring informed consent is obtained,
• Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
• Documenting all care in accordance with mandatory and local requirements

One capsule contains: Bifidobacterium bifidum 1 billion colony-forming units (CFU) and Lactobacillus acidophilus 1 billion CFU

Dose and Indications

Probiotic used to reduce all-cause mortality and necrotising enterocolitis

Dose (oral)

For neonates born at less than 32 weeks gestational age AND receiving at least 1mL feed every 4hrs

<table>
<thead>
<tr>
<th>Current enteral feed</th>
<th>Dose of Infloran®</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤1mL per hour</td>
<td>Half capsule per day (1ml reconstituted)</td>
</tr>
<tr>
<td>&gt;1mL per hour</td>
<td>One capsule per day (2ml reconstituted)</td>
</tr>
</tbody>
</table>

To continue until 34 weeks of corrected age

Preparation and Administration

Oral

Mix one capsule with 2mL of expressed breast milk or formula (whatever the neonate is being given). If the supply of breast milk is limited, Infloran® can be made up in sterile water.

Give as a single BOLUS dose.

Discard the remaining mixture if there is any.
Probiotic (Infloran®)
bifidobacterium bifidim and lactobacillus acidophilus capsule

Adverse Effects

Loose stools, sepsis

Monitoring

Sepsis

Practice Points

Contraindicated in neonates with sepsis, critical illness, necrotising enterocolitis, spontaneous intestinal perforation and small bowel stoma. Can be initiated on consultant discretion in the above population once intestinal mucosal integrity is thought to be achieved.

Not to be used when the neonate is nil by mouth

Not to be added to perfuser feeds or given over time. Always given as a single bolus dose.

Babies with extreme growth restriction (less than 1500g after 32 weeks gestation) may be eligible for Infloran®

If there is a concern about tolerance of additional milk for infants on very low rate feeds administration should be discussed with the treating consultant.

References

Al Faleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotising enterocolitis in preterm infants (Cochrane review), 2014


Probiotic (Infloran®)

bifidobacterium bifidim and lactobacillus acidophilus capsule

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 16/05/2024
ISBN number: 978-1-74243-945-7
PDS reference: CG199
Policy history:

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>16/05/2019</td>
<td>V3.1</td>
<td>SA Safety and Quality Strategic Governance Committee</td>
<td>TGA product registration</td>
</tr>
<tr>
<td>2/03/2018</td>
<td>V3</td>
<td>SA Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed due to a change in product</td>
</tr>
<tr>
<td>28/04/2017</td>
<td>V2</td>
<td>SA Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed due to a change in product</td>
</tr>
<tr>
<td>1/10/2014</td>
<td>V1</td>
<td>SA Safety and Quality Strategic Governance Committee</td>
<td>Original SA Safety and Quality Strategic Governance Committee approved version.</td>
</tr>
</tbody>
</table>